Drug Profile
Tetrandrine - CBA Pharma
Alternative Names: CBT-1; NSC-77037Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator CBA Pharma
- Developer CBA Pharma; National Cancer Institute (USA)
- Class Alkaloids; Antiarrhythmics; Antihypertensives; Antimalarials; Antineoplastics; Benzylisoquinolines; Small molecules
- Mechanism of Action Calcium channel antagonists; Immunosuppressants; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Cancer
- Phase III Non-small cell lung cancer
- Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Ovarian cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
- No development reported Sarcoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Sarcoma(Adjunctive treatment, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 22 Feb 2022 Tetrandrine is still in phase I trial for Sarcoma (Adjunctive treatment, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (CBA pharma pipeline)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Sarcoma(Adjunctive treatment, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)